Zafgen Inc. (ZFGN) announced after the close Tuesday that it has suspended its development of Beloranib. The company has decided to refocus its resources on the development of ZGN-1061. Zafgen also announced that it will reduced its workforce by about 34 percent.
from RTT - Before the Bell http://ift.tt/2a2AF5l
via IFTTT
No comments:
Post a Comment